公开(公告)号：US20230174512A1

公开(公告)日：2023-06-08

申请号：US17922804

申请日：2021-05-04

Applicant: QILU REGOR THERAPEUTICS INC.

Inventor： Zhilong Hu ,  Hu He ,  Fei Zhang ,  Wenge Zhong ,  Xiaotian Zhu

IPC: C07D401/14 ,  A61K45/06 ,  A61P35/00

CPC classification number: C07D401/14 ,  A61K45/06 ,  A61P35/00

Abstract: The invention provides a compound represented by the following structural formula: (I) or a pharmaceutically acceptable salt, or a stereoisomer thereof useful for treating cancer.

公开(公告)号：US20240066031A1

公开(公告)日：2024-02-29

申请号：US18373060

申请日：2023-09-26

Applicant: QILU REGOR THERAPEUTICS INC.

Inventor： Zhilong Hu ,  Hu He ,  Fei Zhang ,  Wenge Zhong ,  Xiaotian Zhu

IPC: A61K31/506 ,  A61K31/5377 ,  A61K31/55 ,  A61K45/06 ,  A61P35/00 ,  C07D401/14 ,  C07D405/14 ,  C07D487/04

CPC classification number: A61K31/506 ,  A61K31/5377 ,  A61K31/55 ,  A61K45/06 ,  A61P35/00 ,  C07D401/14 ,  C07D405/14 ,  C07D487/04

Abstract: The invention provides a compound represented by the following structural formula: (I) or a pharmaceutically acceptable salt, or a stereoisomer thereof useful for treating cancer.

公开(公告)号：US20240051956A1

公开(公告)日：2024-02-15

申请号：US18268914

申请日：2021-12-21

Applicant: QILU REGOR THERAPEUTICS INC.

Inventor： Kailiang Wang ,  Zhilong Hu ,  Fei Zhang ,  Wei Huang ,  Teng Feng ,  Fei Xiao ,  Wenge Zhong

IPC: C07D471/04 ,  C07D519/00 ,  A61P35/00

CPC classification number: C07D471/04 ,  C07D519/00 ,  A61P35/00

Abstract: The present disclosure provides a compound of Formula (I) a pharmaceutically acceptable salt or a stereoisomer and their use in, e.g. treating a condition, disease or disorder in which the inhibition of the interaction of SOS 1 and a RAS-family protein or RAC1 is of therapeutic benefit, specifically in treating oncological diseases. This disclosure also features compositions containing the same as well as methods of using and making the same.

公开(公告)号：US20240033264A1

公开(公告)日：2024-02-01

申请号：US18373067

申请日：2023-09-26

Applicant: QILU REGOR THERAPEUTICS INC.

Inventor： Zhilong Hu ,  Hu He ,  Fei Zhang ,  Wenge Zhong ,  Xiaotian Zhu

IPC: A61K31/506 ,  A61P35/00 ,  A61K31/5377 ,  A61K31/55 ,  C07D405/14 ,  C07D487/04 ,  A61K45/06 ,  C07D401/14

CPC classification number: A61K31/506 ,  A61P35/00 ,  A61K31/5377 ,  A61K31/55 ,  C07D405/14 ,  C07D487/04 ,  A61K45/06 ,  C07D401/14

Abstract: The invention provides a compound represented by the following structural formula: (I) or a pharmaceutically acceptable salt, or a stereoisomer thereof useful for treating cancer.

公开(公告)号：US20220296595A1

公开(公告)日：2022-09-22

申请号：US17608915

申请日：2020-05-05

Applicant: QILU REGOR THERAPEUTICS INC.

Inventor： Zhilong Hu ,  Hu He ,  Fei Zhang ,  Xiaotian Zhu ,  Wenge Zhong

IPC: A61K31/506 ,  A61K31/5377 ,  A61K31/55 ,  A61P35/00 ,  C07D405/14 ,  C07D487/04

Abstract: Provided is a compound represented by structural formula (I), or a pharmaceutically acceptable salt, or a stereoisomer thereof useful for treating cancer.